NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
Clinical Trials
12 trialsNCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272957 2020-06-16
A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
Hutchmed
Phase 1 Unknown
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT02333838 2018-08-13
TBF-Cord
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03114670 2017-06-14
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1 Unknown
NCT03080922 2017-04-04
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT01864902 2016-01-28
CART33
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02489929 2015-07-03
Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
Assistance Publique Hopitaux De Marseille
Phase NA Unknown
NCT01503502 2013-04-10
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT00111345 2012-05-23
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
University Hospital Muenster
Phase 2/3 Unknown